Onivyde is primarily used in the treatment of metastatic pancreatic cancer, particularly in patients who have previously been treated with gemcitabine-based therapy. Clinical trials have demonstrated its effectiveness in improving overall survival rates and progression-free survival in these patients. The success of Onivyde has also opened the door for exploring its use in other types of cancers, leveraging the principles of nanotechnology to enhance drug delivery and therapeutic outcomes.
